title: Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease.
abstract: The identification of biochemical markers of Alzheimer's disease (AD) may help in the diagnosis of the disease. Previous studies have shown that Abeta(1-42) is decreased, and tau and phospho-tau are increased in AD cerebrospinal fluid (CSF). Our own studies have identified glycosylated isoforms of acetylcholinesterase (Glyc-AChE) and butyrylcholinesterase (Glyc-BuChE) that are increased in AD CSF. Glyc-AChE is increased in APP (SW) Tg2576 transgenic mice prior to amyloid plaque deposition, which suggests that Glyc-AChE may be an early marker of AD. The aim of this study was to determine whether Glyc-AChE or Glyc-BuChE is increased in CSF at early stages of AD and to compare the levels of these markers with those of Abeta(1-42), tau and phospho-tau. Lumbar CSF was obtained ante mortem from 106 non-AD patients, including 15 patients with mild cognitive impairment (MCI), and 102 patients with probable AD. Glyc-AChE, tau and phospho-tau were significantly increased in the CSF of AD patients compared to non-neurological disease (NND) controls. Abeta(1-42) was lower in the AD patients than in NND controls. A positive correlation was found between the levels of Glyc-AChE or Glyc-BuChE and disease duration. However, there was no clear correlation between the levels of tau, phospho-tau or Abeta(1-42) and disease duration. The results suggest that Glyc-AChE and Glyc-BuChE are unlikely to be early markers of AD, although they may have value as markers of disease progression.
authors.affiliation: Department of Pathology, University of Melbourne, Victoria, Australia.
authors.forename: J
authors.initials: J
authors.lastname: Sáez-Valero
authors.forename: L R
authors.initials: LR
authors.lastname: Fodero
authors.forename: M
authors.initials: M
authors.lastname: Sjögren
authors.forename: N
authors.initials: N
authors.lastname: Andreasen
authors.forename: S
authors.initials: S
authors.lastname: Amici
authors.forename: V
authors.initials: V
authors.lastname: Gallai
authors.forename: H
authors.initials: H
authors.lastname: Vanderstichele
authors.forename: E
authors.initials: E
authors.lastname: Vanmechelen
authors.forename: L
authors.initials: L
authors.lastname: Parnetti
authors.forename: K
authors.initials: K
authors.lastname: Blennow
authors.forename: D H
authors.initials: DH
authors.lastname: Small
mesh_terms: D000110:Acetylcholinesterase / Q000134:cerebrospinal fluid* / Q000378:metabolism; D000368:Aged; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid* / Q000201:enzymology; D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid; D015415:Biomarkers / Q000134:cerebrospinal fluid; D002091:Butyrylcholinesterase / Q000134:cerebrospinal fluid* / Q000378:metabolism; D005260:Female; D006031:Glycosylation; D006801:Humans; D008297:Male; D019636:Neurodegenerative Diseases / Q000134:cerebrospinal fluid / Q000201:enzymology; D010766:Phosphorylation; D013997:Time Factors; D016875:tau Proteins / Q000134:cerebrospinal fluid
chemical_list: D016229:Amyloid beta-Peptides; D015415:Biomarkers; D016875:tau Proteins; D000110:Acetylcholinesterase; D002091:Butyrylcholinesterase